Sign in

Myelodysplastic syndromes: trials that stopped early

Trials on Myelodysplastic syndromes that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

86 stopped trials give a reason in the registry, latest registry update first.

  1. Suspended

    Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

    Reason given in the registry

    “Enrollment on hold pending amendment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.

    Phase
    Phase 1
    Run by
    University of Chicago
    Registry record
    NCT02333162
  2. Terminated

    A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

    Reason given in the registry

    “Slow/low Enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Inmune Bio, Inc.
    Registry record
    NCT05933070
  3. Terminated

    Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

    Reason given in the registry

    “Development discontinued”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Mar 2026.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    Shattuck Labs, Inc.
    Registry record
    NCT05275439
  4. Withdrawn

    Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)

    Reason given in the registry

    “Abandonment of the study project”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2026.

    Ended
    Jul 2024
    Run by
    Assistance Publique - Hôpitaux de Paris
    Registry record
    NCT04953312
  5. Terminated

    Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2026.

    Ended
    Mar 2026
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT03404193
  6. Terminated

    Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Drug supply issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Mar 2026.

    Ended
    May 2025
    Phase
    Phase 1
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT03772925
  7. Withdrawn

    Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

    Reason given in the registry

    “Change in Study Design”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Ossium Health, Inc.
    Registry record
    NCT05170828
  8. Withdrawn

    Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

    Reason given in the registry

    “Drug Source Request”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2026.

    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06284460
  9. Terminated

    Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2026.

    Ended
    Feb 2026
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04160052
  10. Terminated

    A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

    Reason given in the registry

    “As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Jan 2026.

    Ended
    Jan 2025
    Phase
    Phase 1
    Run by
    NextCure, Inc.
    Registry record
    NCT05787496
  11. Terminated

    A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

    Reason given in the registry

    “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jan 2026.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT03946670
  12. Terminated

    Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

    Reason given in the registry

    “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jan 2026.

    Ended
    Oct 2024
    Phase
    Phase 3
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04266301
  13. Terminated

    Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

    Reason given in the registry

    “Drug company withdrew support.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Dec 2025.

    Ended
    Mar 2025
    Phase
    Phase 1/2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT05918055
  14. Terminated

    A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

    Reason given in the registry

    “Slow enrolment”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2025.

    Ended
    Oct 2025
    Phase
    Phase 1
    Run by
    Kahr Medical
    Registry record
    NCT04937166
  15. Terminated

    Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

    Reason given in the registry

    “The study terminated early because the company was longer providing the investigational product.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2025.

    Ended
    Sept 2024
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04874194
  16. Terminated

    To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

    Reason given in the registry

    “Strategic Business Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    Incyte Corporation
    Registry record
    NCT04582539
  17. Terminated

    STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

    Reason given in the registry

    “Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.

    Ended
    Sept 2024
    Phase
    Phase 2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04878432
  18. Terminated

    Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

    Reason given in the registry

    “Business reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT04810611
  19. Terminated

    HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT03940352
  20. Terminated

    ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

    Reason given in the registry

    “The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2025.

    Ended
    Jul 2025
    Phase
    Phase 2
    Run by
    TC Biopharm
    Registry record
    NCT05358808
  21. Terminated

    Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

    Reason given in the registry

    “Lack of Funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2025.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    Vor Biopharma
    Registry record
    NCT04849910
  22. Terminated

    AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

    Reason given in the registry

    “Sponsor decision, unrelated to safety”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Amgen
    Registry record
    NCT05209152
  23. Terminated

    Connect® Myeloid Disease Registry

    Reason given in the registry

    “Business objectives have changed”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.

    Ended
    Oct 2024
    Run by
    Celgene
    Registry record
    NCT01688011
  24. Terminated

    A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

    Reason given in the registry

    “Trial terminated because of lack of efficacy in the short term acute phase.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2025.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Celgene
    Registry record
    NCT02848001
  25. Withdrawn

    Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

    Reason given in the registry

    “cprmc withdrawn”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT06572631
  26. Terminated

    DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

    Reason given in the registry

    “supporting/funding source decided to de-prioritize and stop development of DS-1594”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.

    Ended
    Nov 2023
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04752163
  27. Terminated

    A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “Company Development strategy adjustment\]”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Apr 2025.

    Ended
    Apr 2024
    Phase
    Phase 3
    Run by
    TJ Biopharma Co., Ltd.
    Registry record
    NCT05709093
  28. Withdrawn

    Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

    Reason given in the registry

    “Study disapproved by internal scientific review committee on re-review; study will no longer move forward”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Apr 2025.

    Phase
    Phase 2
    Run by
    University of Florida
    Registry record
    NCT05766514
  29. Terminated

    Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

    Reason given in the registry

    “Interim analysis determined that study reached a safety stopping rule”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Apr 2025.

    Ended
    May 2024
    Phase
    Phase 3
    Run by
    University of Florida
    Registry record
    NCT03016130
  30. Terminated

    A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

    Reason given in the registry

    “The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Mar 2025.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    GlaxoSmithKline
    Registry record
    NCT05424380

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.